10,354 Shares in Provention Bio, Inc. (NASDAQ:PRVB) Bought by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,354 shares of the company’s stock, valued at approximately $109,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Cabot Wealth Management Inc. acquired a new position in Provention Bio in the fourth quarter worth $1,948,000. Bioimpact Capital LLC boosted its holdings in Provention Bio by 25.0% in the third quarter. Bioimpact Capital LLC now owns 740,344 shares of the company’s stock worth $3,332,000 after purchasing an additional 147,909 shares during the period. Parallax Volatility Advisers L.P. boosted its holdings in Provention Bio by 8.9% in the third quarter. Parallax Volatility Advisers L.P. now owns 16,122 shares of the company’s stock worth $73,000 after purchasing an additional 1,322 shares during the period. Raymond James & Associates boosted its holdings in Provention Bio by 44.1% in the third quarter. Raymond James & Associates now owns 18,482 shares of the company’s stock worth $83,000 after purchasing an additional 5,652 shares during the period. Finally, Royal Bank of Canada boosted its holdings in Provention Bio by 166.5% in the third quarter. Royal Bank of Canada now owns 7,769 shares of the company’s stock worth $35,000 after purchasing an additional 4,854 shares during the period. Institutional investors and hedge funds own 37.39% of the company’s stock.

Provention Bio Stock Performance

PRVB stock opened at $24.98 on Wednesday. The company has a market capitalization of $2.37 billion, a P/E ratio of -16.33 and a beta of 2.47. The company has a 50-day simple moving average of $23.38 and a 200 day simple moving average of $14.04. Provention Bio, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $25.00. The company has a quick ratio of 1.92, a current ratio of 1.93 and a debt-to-equity ratio of 0.19.

Provention Bio (NASDAQ:PRVB – Get Rating) last posted its quarterly earnings results on Wednesday, March 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Provention Bio had a negative return on equity of 103.36% and a negative net margin of 880.69%. The company had revenue of $10.81 million during the quarter, compared to analysts’ expectations of $7.23 million. Sell-side analysts predict that Provention Bio, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Provention Bio

In other Provention Bio news, major shareholder Sessa Capital (Master), L.P. sold 2,190,549 shares of Provention Bio stock in a transaction that occurred on Friday, April 14th. The stock was sold at an average price of $24.32, for a total transaction of $53,274,151.68. Following the sale, the insider now directly owns 15,567,497 shares of the company’s stock, valued at $378,601,527.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PRVB shares. Cantor Fitzgerald downgraded shares of Provention Bio from an “overweight” rating to a “neutral” rating in a report on Monday, March 13th. HC Wainwright downgraded shares of Provention Bio from a “buy” rating to a “neutral” rating and boosted their price target for the company from $16.00 to $25.00 in a report on Wednesday, March 15th. Jefferies Financial Group downgraded shares of Provention Bio from a “buy” rating to a “hold” rating and set a $25.00 price target for the company. in a report on Tuesday, March 14th. Chardan Capital reduced their price target on shares of Provention Bio from $30.00 to $25.00 and set a “buy” rating for the company in a report on Monday, March 13th. Finally, Sumitomo Mitsui Financial Group reissued a “neutral” rating and set a $25.00 price target (up previously from $15.00) on shares of Provention Bio in a report on Tuesday, March 14th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.83.

Provention Bio Profile

(Get Rating)

Provention Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset.